Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)

Updated HCV clinical guidelines placed direct acting agents (DAAs) as the preferable the first line regimens.

The objective of the study was PE assessment of HCV therapy among G1 naïve patients

Methods: Analysis is based on data of randomized clinical trials and average price of HCV medicines from state auctions placed in state procurement system in 2015.

Results: PTV/OBV/DSV/r cost is 30,5% lower vs PegIFN/RBV/SMV. In comparison with PegIFN/RBV/BCV combination PTV/OBV/DSV/r is cost saving by 10,6% at patients without cirrhosis and 36,2% at patients with cirrhosis. DCV/ASV combination is chipper PTV/OBV/DSV/r and it would be used for G1 naïve patient (cost saving is 9,4-10,4%). DCV/ASV and PTV/OBV/DSV/r SVR12 costs are comparable and significantly lower than PegIFN-based regimen: PegIFN/RBV/SMV and PegIFN/RBV/BCV. 4 weeks stop rules due to therapy inefficiency for PegIFN/RBV/SMV regimen could cut cost by 12,6% и 28,0% among patients without and cirrhosis accordingly. By way PTV/OBV/DSV/r is the most cost effective versus PegIFN/RBV/SMV. PTV/OBV/DSV/r as the first line therapy for PegIFN experienced patients provides budget saving 118,2 thousand RUB or 12,2% of budget.

Conclusion: Right now PTV/OBV/DSV/r regimen is the most cost effective the first line therapy for naïve patients.

1. EASL Recommendations on Treatment of Hepatitis C 2015 // Journal of Hepatology 2015; 63: 199–236.

2. Fried M., Mitchell L., Shiffman M., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection // N. Engl. J. Med. 2002; 347 (13): 975-982.

3. Manns M., McHutchison J., GordonS., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial // Lancet 2001; 358 (9286): 958–965.

4. Poordad F., McCone, Jr. J., Bacon B., et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection // NEJM 2011; 364 (13): 1195-206.

5. Manns M., Marcellin P., Poordad F., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial // Lancet 2014; 384 (9941): 414-26.

6. Jacobson I.M., Dore G.J., Foster G.R., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatmentnaïve patients with chronic hepatitis c virus genotype 1 infection (QUEST-1): a phase 3, randomized, double-blind, placebocontrolled trial // Lancet 2014;384:403-13.

7. Manns M., Pol S., Jacobson I.M., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study // Lancet 2014; 384: 1597– 605.

8. Ferenci P., Bernstein D., Lalezar J., et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV // N Engl J Med 2014; 370:1983–1992.

9. Feld J., Kowdley K.V., Coakley E., et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin // N Engl J Med 2014; 370:1594–1603.

10. Zeuzem S., Jacobson I.M., Baykal T., et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin // N Engl J Med 2014; 370: 1604–1614.

11. Poordad F., Hezode C., Trinh R., et al. ABT-450/rombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis // N Engl J Med. 2014; 370: 1973–1982.

12. Andreone P., Colombo M.G., Enejosa J.V., et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment- experienced patients with HCV genotype 1b infection // Gastroenterol. 2014; 147: 359–365.